

S4 Table. Comparisons of the patient characteristics between the secondary CRS and no surgery groups

Characteristic	Secondary CRS (n=80, %)	No surgery (n=182, %)	p-value
<i>BRCA</i> mutational status			0.234
<i>BRCA1</i> mutation	16 (20.0)	54 (29.7)	
<i>BRCA2</i> mutation	8 (10.0)	13 (7.1)	
Wild-type	56 (70.0)	115 (63.2)	
Histology			0.007
High-grade serous	59 (73.8)	159 (87.4)	
Non-high-grade serous	21 (26.3)	23 (12.6)	
Residual tumor at first CRS			0.002
Complete resection	67 (83.8)	118 (64.8)	
Residual disease	13 (16.3)	64 (35.2)	
Platinum-free interval (mo)			
Median (range)	22.8 (6.2-161.9)	12.3 (6.0-172.3)	<0.001
≥ 6 and < 12	20 (25.0)	86 (47.3)	0.001
≥ 12	60 (75.0)	96 (52.7)	
Age at recurrence (yr)			
Mean±SD	55.0±9.3	58.0±9.6	0.022
CA-125 at recurrence (IU/mL)			
Median (range) ^{a)}	62.3 (2.5-987.0)	112.4 (2.2-8,320.0)	<0.001
Ascites >500 mL at recurrence			0.617
No	70 (87.5)	155 (85.2)	
Yes	10 (12.5)	27 (14.8)	
AGO score			0.001
Negative	19 (23.8)	81 (44.5)	
Positive	61 (76.3)	101 (55.5)	
Second-line chemotherapy			0.386
Paclitaxel-Carboplatin-BEV	26 (32.5)	71 (39.0)	
Gemcitabine-Carboplatin-BEV	1 (1.3)	2 (1.1)	
Paclitaxel-Carboplatin	31 (38.8)	60 (33.0)	
PLD-Carboplatin	13 (16.3)	31 (17.0)	
Docetaxel-Carboplatin	7 (8.8)	5 (2.7)	
Gemcitabine-Carboplatin	2 (2.5)	7 (3.8)	
Belotecan-Cisplatin	0	4 (2.2)	
Topotecan-Cisplatin	0	1 (0.5)	
Irinotecan-Cisplatin	0	1 (0.5)	
Second-line chemotherapy cycles			
Median (range)	6 (3-9)	6 (2-12)	0.259
<6	8 (10.0)	25 (13.7)	0.090
6	64 (80.0)	122 (67.0)	
≥7	8 (10.0)	35 (19.2)	
Maintenance therapy			
Two categories			0.148
No	46 (57.5)	87 (47.8)	
Yes	34 (42.5)	95 (52.2)	
Three categories			0.272
No	46 (57.5)	87 (47.8)	
BEV	22 (27.5)	68 (37.4)	
PARPi	12 (15.0)	27 (14.8)	
Four categories			0.145
No	46 (57.5)	87 (47.8)	
BEV	22 (27.5)	68 (37.4)	
OLA	8 (10.0)	24 (13.2)	
NIRA	4 (5.0)	3 (1.6)	

Values are presented as number (%) unless otherwise indicated. AGO, Arbeitsgemeinschaft Gynäkologische Onkologie; BEV, bevacizumab; CA-125, cancer antigen 125; CRS, cytoreductive surgery; NIRA, niraparib; OLA, olaparib; PARPi, poly(ADP-ribose) polymerase inhibitor; PLD, pegylated liposomal doxorubicin; SD, standard deviation. ^{a)}Missing data: 10.